Drugs & Therapy Perspectives

, Volume 27, Issue 4, pp 1–4 | Cite as

Aztreonam lysine for inhalation solution: a guide to its use in cystic fibrosis

Drug and Profile Reports


  1. 1.
    Plosker GL. Aztreonam lysine for inhalation solution in cystic fibrosis. Drugs 2010; 70(14): 1843–55PubMedCrossRefGoogle Scholar
  2. 2.
    Cayston powder and solvent for nebuliser solution: summary of product characteristics. London: European Medicines Agency, 2010 SepGoogle Scholar
  3. 3.
    Cayston® (aztreonam for inhalation solution): US prescribing information. Foster City (CA): Gilead Sciences, Inc., 2010 FebGoogle Scholar
  4. 4.
    McCoy K, Retsch-Bogart G, Gibson RL, et al. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) [poster no. 142]. 31st European Cystic Fibrosis Conference; 2008 Jun 11–14; PragueGoogle Scholar
  5. 5.
    McCoy K, Retsch-Bogart G, Gibson RL, et al. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis [poster no. 418]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23–25; Orlando (FL)Google Scholar
  6. 6.
    Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010 Nov; 45(11): 1121–34PubMedCrossRefGoogle Scholar
  7. 7.
    Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135(5): 1223–32PubMedCrossRefGoogle Scholar
  8. 8.
    McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178(9): 921–8PubMedCrossRefGoogle Scholar
  9. 9.
    Wainwright C, Nakamura C, Geller DE, et al. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA) [abstract no. 81]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16–19; ValenciaGoogle Scholar
  10. 10.
    Assael BM, La Rosa M, Knoop C, et al. Aztreonam for inhalation solution (AZLI) head to head trial, a comparative trial vs. tobramycin nebuliser solution (TNS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (PA): results of first treatment cycle [abstract]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16–19; ValenciaGoogle Scholar
  11. 11.
    Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnarie-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135(6): 1610–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations